Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of Merrimack's development programs, including four clinical studies in distinct indications and six candidates in preclinical development, fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes.
Copyright Nasdaq. Minimum 15 minutes delayed.
February 22, 2018 at 9:30 AM EST
2018 RBC Capital Markets Global Healthcare Conference
January 11, 2018 at 9:00 AM PST
36th Annual J.P. Morgan Healthcare Conference
November 8, 2017 from 8:30 AM to 8:30 AM EST
- November 8, 2017